Polivy struck by NICE ‘no’
NICE is citing “substantial uncertainty in the submitted data” as a reason not to recommend the drug, as well as a lack of “strong long-term evidence on remission with the treatment.”
Read More
Tag: DLBCL
EU approves first CAR-T therapies
European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.
Read More
Speedy EU, US review for Novartis’ CAR-T therapy Kymriah
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR-T therapy Kymriah.
Read More
Novartis files CAR-T therapy in Europe
Novartis has submitted an application to the European Medicines Agency for its CAR-T therapy CTL019 for two haematological indications.
Read More
Novartis’ CAR-T shows durable response in lymphoma patients
Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR-T cell therapy in a mid-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
